A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
Immunome, Inc.
Study ID
NCT07505771
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 177Lu-IM-3050 — DRUG
    177Lu-IM-3050 is a FAP-directed radiopharmaceutical

Study Details

IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.

Key Dates

Start date
Apr 30, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2034

Study Design

Enrollment
105 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 177Lu-IM-3050
    177Lu-IM-3050 administered intravenously on a 6-week cycle

Primary Outcome Measure

Safety and tolerability of 177Lu-IM-3050 in participants with advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs) [ Time Frame: From first dose of 177Lu-IM-3050 through at least 42 days following last dose of study treatment serious and up to approximately 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Excel Diagnostics and Nuclear Oncology CenterHoustonTexas77042
Ebrahim Delpassand, MD
[email protected]
713-781-6200

Find similar trials in Houston, TX

By research site
Excel Diagnostics and Nuclear Oncology Center· Houston, TX

Related Studies